Developing a Safe Intravenous Sotalol Dosing Regimen
Somberg JC, Preston RA, Ranade V, Molnar J. Developing a safe intravenous sotalol dosing regimen. Am J Ther. 2010;17(4):365-372. doi:10.1097/MJT.0b013e3181ea3184
In this randomized, 2-treatment, 2-period crossover study, pharmacokinetic methods were used to study maximum serum concentrations in 18 patients in order to determine the optimal intravenous administration regimen. Intravenous sotalol (75 mg) administered over 2.5 hours resulted in a significantly greater maximum concentration than oral sotalol (80 mg). https://pubmed.ncbi.nlm.nih.gov/20562595/
Sotalol IV MAY CAUSE LIFE THREATENING PROARRYTHMIA and is associated with QT interval prolongation. Please see the full prescribing information including boxed warning, precautions, and contraindications at altathera.com/sotalol-iv-pi/.